HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Platelet-Derived Growth Factor alpha Receptor

Subscribe to New Research on Platelet-Derived Growth Factor alpha Receptor

A PDGF receptor that binds specifically to both PDGF-A chains and PDGF-B chains. It contains a protein-tyrosine kinase activity that is involved in SIGNAL TRANSDUCTION.

Also Known As:

Receptor, Platelet-Derived Growth Factor alpha; CD140a Antigen; PDGFR2; PDGFRalpha; Antigen, CD140a; Platelet Derived Growth Factor alpha Receptor; Antigens, CD140a; CD140a Antigens; PDGF alpha Receptor; PDGF-R-alpha; Receptor, PDGF alpha

Networked: 196 relevant articles (3 outcomes, 17 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Loizos, Nick: 4 articles (02/2010 - 03/2005)
2.	van Zoelen, Everardus J J: 4 articles (07/2009 - 12/2002)
3.	Toepoel, Mascha: 4 articles (07/2009 - 12/2002)
4.	Nistér, M: 4 articles (08/2006 - 11/2000)
5.	Schimanski, Carl C: 3 articles (02/2010 - 03/2008)
6.	Moehler, Markus: 3 articles (02/2010 - 03/2008)
7.	Gockel, Ines: 3 articles (02/2010 - 03/2008)
8.	Galle, Peter R: 3 articles (02/2010 - 03/2008)
9.	Afink, Gijs B: 3 articles (08/2009 - 12/2002)
10.	Joosten, Paul H L J: 3 articles (07/2009 - 12/2002)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2005 - "These data suggest that 3G3 may be useful for the treatment of tumors that express PDGFRalpha." 02/15/2010 - "The results of preclinical studies and the frequent expression of PDGFRalpha in many types of cancer and in cancer-associated stroma support a rationale for the clinical development of IMC-3G3. " 11/01/2009 - "Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFRalpha/KIT inhibitors." 04/01/2009 - "These studies demonstrate that combined inhibition of PDGFRalpha and -beta results in markedly decreased tumor growth in vivo because of impaired recruitment of periendothelial cells." 03/01/2010 - "Investigated cofactors included age, sex, performance status (PS), primary tumor site, time from diagnosis, prior therapies, baseline biology, and KIT/PDGFRalpha mutations for a subset of 772 patients. " Order ALL the reference details at left...
2.	Hypereosinophilic Syndrome (Loeffler Endocarditis) 11/01/2009 - "The pathogenesis of hypereosinophilic syndrome (HES) in some patients is highly dependent on FIP1-Like-1 (FIP1L1)-platelet-derived growth factor receptor alpha (PDGFRalpha), which can generate sustained activation signaling to maintain a cell malignant phenotype. " 11/01/2008 - "[FIP1L1/PDGFRalpha fusion gene-negative chronic eosinophilic leukemia with t(5;12)(q31;p13): a case report and review of literatures]" 09/15/2008 - "FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome." 11/12/2006 - "The diagnosis of chronic myeloid leukemia and certain types of chronic eosinophilic leukemia are based on the detection of fusion genes (in chronic myeloid leukemia the BCR/ABL fusion gene, and in chronic eosinophilic leukemia the FIP1L1-PDGFRalpha gene). " 04/01/2008 - "PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment." Order ALL the reference details at left...
3.	Hyperalgesia 10/26/2005 - "Moreover, thermal hyperalgesia and tactile allodynia induced by thrombin in normal mice were virtually eliminated by intrathecal pretreatment with PDGFRalpha/Fc. " 10/26/2005 - "Thermal hyperalgesia and tactile allodynia induced by sciatic nerve ligation were also suppressed by repeated intrathecal injection of either the PDGF alpha receptor (PDGFRalpha)/Fc chimera protein or the PDGFR-dependent tyrosine kinase inhibitor AG17 [(3,5-di-tert-butyl-4-hydroxybenzylidene)-malononitrile]. " Order ALL the reference details at left...
4.	Glioma (Gliomas) 01/01/2008 - "Irrespective of the grade and morphological diagnosis of gliomas, glioma cells concomitantly expressed PDGFRalpha, A2B5, O4, CD44 and GFAP. " 01/01/2008 - "Six low-grade and 17 high-grade glioma specimens were flow-cytometrically analyzed for markers characteristics of stem cells (CD133); glial progenitors (PDGFRalpha, A2B5, O4, and CD44); and late oligodendrocyte progenitors (O1). " 06/02/2005 - "Array and quantitative real-time PCR analysis demonstrated elevated expression similar to Pdgfralpha of retrovirally tagged genes Abhd2, Ddr1, Fos, Ng2, Ppfibp1, Rad51b and Sulf2 in both glioma types compared to neonatal and adult normal brain. " 01/01/1996 - "Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas." 01/01/1996 - "The aim of this study was to examine platelet-derived growth factor alpha receptor (PDGFR-alpha) expression in gliomas of various degrees of malignancy and to correlate the findings with genetic alterations present in the same tumor samples. " Order ALL the reference details at left...
5.	Chondrosarcoma 04/01/2006 - "PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma." 12/01/2001 - "Because PDGF-alpha receptor expression positively correlates with the aggressiveness of chondrosarcoma, it may be considered as a possible target for novel therapeutic strategies." 12/01/2001 - "Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome." 12/01/2001 - "PDGF-alpha receptor expression was significantly higher in grade 3 chondrosarcomas compared with grade 2 (p = 0.022) and grade 1 tumors (p = 0.002). " 12/01/2001 - "In this study we wanted to determine the expression of PDGF-AA and PDGF-alpha receptor in conventional chondrosarcomas and to compare the results with those obtained from benign enchondromas and non-neoplastic cartilage tissue. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	imatinib (Gleevec)
2.	Thrombin
3.	Platelet-Derived Growth Factor
4.	Antibodies
5.	Insulin (Novolin)
6.	Transforming Growth Factors (Transforming Growth Factor)
7.	Insulin-Like Growth Factor II (Somatomedin A)
8.	platelet-derived growth factor AB
9.	Formaldehyde (Formol)
10.	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)

Related Therapies and Procedures

1.	Ligation
2.	Transplants (Transplant)
3.	Drug Therapy (Chemotherapy)
4.	Homologous Transplantation (Allograft)
5.	Spinal Injections

blog comments powered by Disqus

TREATMENT OPTIONS
for Neoplasms,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 20715 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>